OP Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

OP Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.21M	Hold	56,060	–	–	0.03%	346
2026 Q1	$3.17M	Buy	+56,060	New	+$3.27M	0.03%	349
2025 Q4	–	Sell	-22,635	Closed	-$1.23M	–	782
2025 Q3	$1.23M	Hold	22,635	–	–	0.02%	557
2025 Q2	$1.24M	Buy	22,635 +2,127	+10%	+$125K	0.02%	554
2025 Q1	$1.45M	Buy	+20,508	New	+$1.38M	0.02%	508

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

OP Asset Management's BMRN Position: Q2 2026 in Review

OP Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 56,060 shares worth $3.21M. The position accounts for 0.03% of the portfolio, ranked #346.

OP Asset Management first reported a position in BMRN in Q1 2025 and has held it in 5 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

OP Asset Management held 56,060 shares of BioMarin Pharmaceuticals worth $3.21M as of Q2 2026.
OP Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up 0.03% of OP Asset Management's portfolio in Q2 2026, its #346 holding.
OP Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.